|
End-of-day quote
Shanghai S.E.
23/10/2026
|
5-day change | 1st Jan Change | ||
| 18.16 CNY | -0.77% |
|
-3.09% | +3.06% |
| 02:02pm | DaShenLin Pharmaceutical Completes Maturity Redemption of Convertible Bonds | MT |
| 14/10 | Dashenlin Pharmaceutical to Redeem Dashen Convertible Bonds | MT |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,307 | 37,585 | 28,359 | 17,151 | 20,066 | 20,682 | - | - |
| Change | - | 12.85% | -24.55% | -39.52% | 17% | 3.07% | - | - |
| Enterprise Value (EV) 1 | 32,838 | 36,233 | 27,369 | 15,778 | 16,831 | 17,341 | 16,921 | 16,626 |
| Change | - | 10.34% | -24.46% | -42.35% | 6.67% | 3.03% | -2.42% | -1.74% |
| P/E | 42.1x | 36.3x | 24.2x | 18.6x | 16.3x | 13.9x | 12.1x | 10.7x |
| PBR | 6.3x | 6.24x | 4.16x | 2.49x | 2.72x | 2.64x | 2.42x | 2.25x |
| PEG | - | 1.2x | 1.8x | -0.9x | 0.5x | 0.7x | 0.8x | 0.8x |
| Capitalization / Revenue | 1.99x | 1.77x | 1.16x | 0.65x | 0.73x | 0.7x | 0.64x | 0.58x |
| EV / Revenue | 1.96x | 1.71x | 1.12x | 0.6x | 0.61x | 0.59x | 0.52x | 0.46x |
| EV / EBITDA | 13.6x | 19.2x | 12.9x | 4.65x | 4.39x | 4.53x | 4.02x | 3.57x |
| EV / EBIT | 31.6x | 25.5x | 16.8x | 10.5x | 8.26x | 7.46x | 6.4x | 5.55x |
| EV / FCF | 117x | 13.1x | 19.7x | 9.51x | 3.44x | 10.1x | 6.05x | 5.12x |
| FCF Yield | 0.86% | 7.61% | 5.09% | 10.5% | 29.1% | 9.94% | 16.5% | 19.5% |
| Dividend per Share 2 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.49 | 0.9418 | 1.043 | 1.222 |
| Rate of return | 1.19% | 1.52% | 1.24% | 2.06% | 2.78% | 5.19% | 5.74% | 6.73% |
| EPS 2 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.08 | 1.304 | 1.5 | 1.701 |
| Distribution rate | 50% | 55% | 30.1% | 38.3% | 45.4% | 72.2% | 69.5% | 71.8% |
| Net sales 1 | 16,759 | 21,248 | 24,531 | 26,497 | 27,502 | 29,540 | 32,521 | 35,823 |
| EBITDA 1 | 2,408 | 1,883 | 2,119 | 3,395 | 3,833 | 3,828 | 4,204 | 4,651 |
| EBIT 1 | 1,041 | 1,421 | 1,632 | 1,501 | 2,038 | 2,324 | 2,643 | 2,997 |
| Net income 1 | 791.2 | 1,036 | 1,166 | 914.8 | 1,235 | 1,486 | 1,711 | 1,937 |
| Net Debt 1 | -469.2 | -1,352 | -989.8 | -1,373 | -3,236 | -3,340 | -3,760 | -4,056 |
| Reference price 2 | 29.24 | 33.00 | 24.90 | 15.06 | 17.62 | 18.16 | 18.16 | 18.16 |
| Nbr of stocks (in thousands) | 11,38,968 | 11,38,947 | 11,38,902 | 11,38,848 | 11,38,848 | 11,38,855 | - | - |
| Announcement Date | 27/04/22 | 27/04/23 | 28/04/24 | 25/04/25 | 23/04/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.04x | 0.59x | 4.57x | 5.15% | 312.18Cr | |
| 17.24x | 0.71x | 10.59x | -.--% | 1.55TCr | |
| 23.63x | 0.98x | 10.63x | 1.9% | 704.52Cr | |
| 17.08x | 0.76x | 7.93x | 2.19% | 656.83Cr | |
| 20.63x | 0.35x | 5.52x | 2.21% | 629.8Cr | |
| 19.65x | 0.71x | 12.35x | 1.11% | 586.86Cr | |
| 16.48x | 1.03x | 7.22x | 2.56% | 465.82Cr | |
| 16.09x | 0.96x | 7.22x | 4.02% | 326.66Cr | |
| 15.6x | 0.46x | 7.56x | 1.35% | 318.81Cr | |
| 13.51x | 1.16x | 7.14x | 6.01% | 295.77Cr | |
| Average | 17.40x | 0.77x | 8.07x | 2.65% | 584.31Cr | |
| Weighted average by Cap. | 18.03x | 0.75x | 8.81x | 1.91% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
